New eye drop hopes to soothe dry eye sufferers

NCT ID NCT07656688

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study tests a new eye drop called HUC1-394 in 150 adults with moderate to severe dry eye disease. Participants will use the drops or a placebo for a period to see if the drug reduces eye surface damage and improves symptoms. The goal is to find the best dose and frequency.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HUC1-394 eye drops
What this could lead to
If it works, this could lead to a new treatment option for people with moderate to severe dry eye disease, reducing eye damage and discomfort.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yonsei University Health System, Severance Hospital

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.